Table 5.
Comparison of urodynamic parameters between the two groups after treatment
| Urodynamic | Qmax (mL/s) | Qave (mL/s) | Vt(s) | Pdet. Qmax (cmH2O) | MCC (ml) | FS (ml) | BC (ml/cmH2O) |
|---|---|---|---|---|---|---|---|
| Tolterodine (n = 30) | 27.26 ± 4.43 | 12.62 ± 1.49 | 23.6 ± 4.9 | 32.5 ± 7.8 | 519.1 ± 81.6 | 225.3 ± 44.5 | 4.50 ± 0.73 |
| Intravaginal Estrogen (n = 28) | 25.70 ± 4.59 | 12.36 ± 1.66 | 23.4 ± 5.0 | 30.6 ± 7.2 | 479.6 ± 57.1 | 209.6 ± 42.1 | 4.66 ± 0.69 |
| F | 1.727 | 0.392 | 0.009 | 0.867 | 4.503 | 1.881 | 0.684 |
| P | 0.194 | 0.534 | 0.924 | 0.356 | 0.038* | 0.176 | 0.412 |
*
Compared to the 12-week follow-up within Intravaginal Estrogen group.
Qmax: maximum urinary flow rate; Qave: mean uroflow rate; Vt: urination time; Pdet. Qmax: maximal detrusor pressure; MCC: maximum bladder capacity; FS: bladder initial sensing capacity; BC: bladder compliance.